Menu Search
Equities

Centene Corp

0HVB:LSE

Centene Corp

Actions
  • Price (USD)59.66
  • Today's Change1.49 / 2.56%
  • Shares traded18.00k
  • 1 Year change-18.50%
  • Beta--
Data delayed at least 20 minutes, as of Nov 14 2024 16:42 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Centene Corporation is a healthcare company. The Company provides services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. It provides a range of managed healthcare products and services, primarily through Medicaid, Medicare, and commercial products. Its segments include Medicaid, Medicare, Commercial and Other. It offers Medicaid and Medicare members (including Medicare Prescription Drug Plans) as well as individuals and families served by the Health Insurance Marketplace and the TRICARE program. It also contracts with other healthcare and commercial organizations to provide a variety of specialty services focused on treating the whole person. Medicaid program provides health insurance to low-income families and individuals with disabilities. Medicare is a federal health insurance program for people ages 65 and over, which also covers people under 65 with certain disabilities and people with end-stage renal diseases.

  • Revenue in USD (TTM)161.73bn
  • Net income in USD3.07bn
  • Incorporated2001
  • Employees67.70k
  • Location
    Centene Corp7700 Forsyth BlvdST. LOUIS 63105-1807United StatesUSA
  • Phone+1 (314) 725-4477
  • Fax+1 (302) 655-5049
  • Websitehttps://www.centene.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.